Literature DB >> 35250013

Choroidal Nevus Regression in the Setting of Checkpoint Inhibition Immunotherapy.

William Foulsham1,2, David H Abramson1,2, Jasmine H Francis1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35250013      PMCID： PMC9078091          DOI： 10.1097/IAE.0000000000003467

Source DB:  PubMed          Journal:  Retina        ISSN： 0275-004X            Impact factor:   3.975


× No keyword cloud information.
  5 in total

Review 1.  Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis.

Authors:  Hansje-Eva Teulings; Jacqueline Limpens; Sophia N Jansen; Aeilko H Zwinderman; Johannes B Reitsma; Phyllis I Spuls; Rosalie M Luiten
Journal:  J Clin Oncol       Date:  2015-01-20       Impact factor: 44.544

2.  Development of Poliosis Following Checkpoint Inhibitor Treatment for Cutaneous Melanoma.

Authors:  Lilangi S Ediriwickrema; Catherine Y Liu; Don O Kikkawa; Bobby S Korn
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2019 Sep/Oct       Impact factor: 1.746

3.  Immune Checkpoint Inhibitor Therapy as an Eye-Preserving Treatment for Locally Advanced Conjunctival Melanoma.

Authors:  Bennett Yau-Bun Hong; Joshua R Ford; Isabella C Glitza; Carlos A Torres Cabala; Michael Tetzlaff; Victor G Prieto; Richard Parker; Claire Daniel; Bita Esmaeli
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2021 Jan-Feb 01       Impact factor: 2.011

4.  Progressive choroidal thinning (leptochoroid) and fundus depigmentation associated with checkpoint inhibitors.

Authors:  Julia Canestraro; Korey A Jaben; Jedd D Wolchok; David H Abramson; Jasmine H Francis
Journal:  Am J Ophthalmol Case Rep       Date:  2020-06-26

5.  Regression of pigmented lesions in a patient with metastatic melanoma treated with immunotherapy.

Authors:  Zachary Schwager; Mary E Laird; Jo-Ann Latkowski
Journal:  JAAD Case Rep       Date:  2018-04-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.